Biotech and Pharmaceuticals
Healthy Returns: Biotech and pharma M&A is off to a good start in 2025 — but will it last?
The New York Stock Exchange welcomes Johnson & Johnson (NYSE: JNJ) on Dec. 5th, 2023. NYSE Group A version of this article first appeared in CNBC’s Healthy Returns newsletter, which brings the latest health-care news straight to your inbox. Subscribe here to receive future editions. I’m back in New York City after spending nearly a […]
Read More
FDA approves Johnson & Johnson’s nasal spray for depression as standalone treatment
This photo provided by Janssen Global Services shows Spravato nasal spray. Janssen Global Services via AP The Food and Drug Administration on Tuesday approved Johnson & Johnson‘s nasal spray to be used alone in adults with a major depressive disorder that is difficult to treat, as sales of the drug grow. The spray, called Spravato, […]
Read More
Goldman Sachs sees ‘significant’ investment opportunities as the population ages
The world is getting older — and with that demographic change comes “significant” investment opportunities, according to Goldman Sachs. Fertility rates are declining and people are living longer, resulting in an older demographic taking a larger share of the total population. The global population is expected to rise by about 20% through 2050, said analyst […]
Read More
Ozempic is in the next round of Medicare drug price negotiations. See the full list of 15 medications
U.S. President Joe Biden speaks about prescription drug costs during an event at NHTI Concord Community College in Concord, New Hampshire, U.S., October 22, 2024. REUTERS/Elizabeth Frantz Elizabeth Frantz | Reuters The Biden administration on Friday unveiled the next 15 prescription drugs that will be subject to price negotiations between manufacturers and Medicare, kicking off […]
Read More
Medicare’s new $2,000 cap on out-of-pocket drug costs could save enrollees thousands, AARP says
Most Medicare patients who hit the new $2,000 cap on out-of-pocket spending for prescription drugs could see massive savings, despite changes in premiums, according to a report released Thursday by AARP. The findings suggest the cap could be a huge benefit to older adults in Medicare who struggle to afford high-cost drugs for cancer, rheumatoid […]
Read More
Stocks pop on cool inflation, hot bank earnings — plus, new rules on biotech exports to China
Every weekday, the CNBC Investing Club with Jim Cramer releases the Homestretch — an actionable afternoon update, just in time for the last hour of trading on Wall Street. Markets: Wall Street surged Wednesday thanks to the second encouraging inflation report this week and a batch of strong bank earnings. The consumer price index, excluding […]
Read More
Bristol Myers Squibb says Alzheimer’s is the biggest market for new schizophrenia drug
The Bristol Myers Squibb research and development center at Cambridge Crossing in Cambridge, Massachusetts, US, on Wednesday, Dec. 27, 2023. Adam Glanzman | Bloomberg | Getty Images Bristol Myers Squibb believes Alzheimer’s is the largest market for its newly approved schizophrenia drug, Cobenfy, which it expects to eventually generate billions of dollars in revenue. In […]
Read More
U.S. imposing new export controls on biotech equipment over China concerns
The Department of Commerce building is seen before an expected report of new home sales numbers in Washington, January 26, 2022. Joshua Roberts | Reuters The U.S. Commerce Department said Wednesday it is imposing new export controls on biotechnology equipment and related technology because of national security concerns tied to artificial intelligence and data science. […]
Read More
Healthy Returns: From Eli Lilly to Amazon, here are the latest health-care deals
A version of this article first appeared in CNBC’s Healthy Returns newsletter, which brings the latest health-care news straight to your inbox. Subscribe here to receive future editions. Good afternoon from San Francisco! This week, Ashley and I are attending the annual JPMorgan Health Care Conference – the largest gathering of biotech and pharma execs, […]
Read More
Eli Lilly shares drop as drugmaker cuts revenue guidance on weight loss drug demand
The Eli Lilly & Co. logo at the company’s Digital Health Innovation Hub facility in Singapore, on Thursday, Nov. 14, 2024. Ore Huiying | Bloomberg | Getty Images Eli Lilly cut its revenue guidance on Tuesday as it said demand for its weight loss and diabetes drugs would not meet its lofty expectations. The drugmaker’s […]
Read More